Seeking Alpha

Bristol Myers Squibb (BMY) +2.3% premarket after results from an early-stage study show its...

Bristol Myers Squibb (BMY) +2.3% premarket after results from an early-stage study show its BMS-936658 experimental drug that helps the immune system attack cancer cells can reduce the size of tumors in patients with melanoma and non-small cell lung cancers. (also)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs